Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
114
datasets available to search
ShareScore release 0.9.0
Dataset results
114 results for “CXCR4”
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors
<p>These are RAW data datasets of the following final paper</p> <p>Trotta, A.M., Aurilio, M., D'Alterio, C., Ieranò, C., Di Martino, D., Barbieri, A., Luciano, A., Gaballo, P., Santagata, S., Portella, L., Tomassi, S., Marinelli, L., Sementa, D., Novellino, E., Lastoria, S., Scala, S., Schottelius, M., Di Maro, S.</p> <p>Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors, (2021) Journal of Medicinal Chemistry, 64 (6), pp. 3449-3461. ISSN 00222623</p> <p>https://doi.org/10.1021/acs.jmedchem.1c00066</p> <p>Abstract</p> <p>The recently reported CXCR4 antagonist 3 (Ac-Arg-Ala-[DCys-Arg-2Nal-His-Pen]-CO2H) was investigated as a molecular scaffold for a CXCR4-targeted positron emission tomography (PET) tracer. Toward this end, 3 was functionalized with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononanetriacetic acid (NOTA). On the basis of convincing affinity data, both tracers, [68Ga]NOTA analogue ([68Ga]-5) and [68Ga]DOTA analogue ([68Ga]-4), were evaluated for PET imaging in “in vivo” models of CHO-hCXCR4 and Daudi lymphoma cells. PET imaging and biodistribution studies revealed higher CXCR4-specific tumor uptake and high tumor/background ratios for the [68Ga]NOTA analogue ([68Ga]-5) than for the [68Ga]DOTA analogue ([68Ga]-4) in both in vivo models. Moreover, [68Ga]-4 and [68Ga]-5 displayed rapid clearance and very low levels of accumulation in all nontarget tissues but the kidney. Although the high tumor/background ratios observed in the mouse xenograft model could partially derive from the hCXCR4 selectivity of [68Ga]-5, our results encourage its translation into a clinical context as a novel peptide-based tracer for imaging of CXCR4-overexpressing tumors.</p> <p> </p> <p> </p>
CXCR4 antibody specific staining
<p>CXCR4 antibody (#PA3305, Invitrogen Inc., USA) is truly reacting to the antigens in question (specific staining). </p> <p>Tissue: Oral cancer (20X magnification).</p> <p> </p>
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
ClinicalTrials.gov study NCT03225716. IPD Sharing: NO. Countries: 1. Publications: 2.
Biological role of tumor/stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 advanced ovarian cancer patients
<p>Row data H-score Biological role of tumor/stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 advanced ovarian cancer patients</p>
Supplementary data to publication "Cellular detection of the chemokine receptor CXCR4 in bovine mammary glands and its distribution and regulation on bovine leukocytes"
<p>Supplementary data to publication "Cellular detection of the chemokine receptor CXCR4 in bovine mammary glands and its distribution and regulation on bovine leukocytes" in Journal of Dairy Science; https://doi.org/10.3168/jds.2021-20799</p>
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
ClinicalTrials.gov study NCT02069080. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
ClinicalTrials.gov study NCT01010880. IPD Sharing: Not stated. Countries: 1. Publications: 1.
CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
ClinicalTrials.gov study NCT06234319. IPD Sharing: NO. Countries: 1. Publications: 1.
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
ClinicalTrials.gov study NCT03436342. IPD Sharing: NO. Countries: 1. Publications: 2.
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
ClinicalTrials.gov study NCT05839483. IPD Sharing: NO. Countries: 1. Publications: 3.
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
ClinicalTrials.gov study NCT05604482. IPD Sharing: NO. Countries: 1. Publications: 0.
CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism
ClinicalTrials.gov study NCT06183554. IPD Sharing: NO. Countries: 1. Publications: 1.
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
ClinicalTrials.gov study NCT04504526. IPD Sharing: NO. Countries: 1. Publications: 2.
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
ClinicalTrials.gov study NCT05255926. IPD Sharing: NO. Countries: 1. Publications: 3.
Development of a new class of radiopharmaceuticals for diagnosis and therapy of CXCR4-expressing malignancies based on the endogenous CXCR4 antagonist EPI-X4
<p>The pathological overexpression of the C-X-C motif chemokine receptor 4 (CXCR4) in more than 23 human cancers designate CXCR4 as a “wide spectrum” molecular target in oncology. In nuclear medicine, radiolabeled molecules can specifically target such cell surface receptors and can be designed for blending diagnostic and therapeutic properties within the same molecule (radio-theranostics). Recently, the applicants have identified an endogenous antagonist of CXCR4, termed EPI-X 4. EPI-X4 is a 16-mer peptide derived from human serum albumin that specifically binds CXCR4 but no other G-protein coupled receptors, without causing receptor activation. Several synthetic derivatives of EPI-X4 with increased affinity for CXCR4, resistance against proteolytic degradation in blood and high systemic retention times have been developed. Radiotheranostics based on EPI-X4 may thus offer new imaging tests and therapeutic options to patients suffering from CXCR4-expressing malignancies. The proposed research project would be the first study aiming to evaluate a new class of radiopharmaceuticals based on an endogenous peptide naturally present in the human body, which may have less off-target effects as compared to small molecules.</p>
Autologous CD4 T-Cells in HIV (C34-CXCR4)
ClinicalTrials.gov study NCT03020524. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
ClinicalTrials.gov study NCT02907099. IPD Sharing: Not stated. Countries: 1. Publications: 0.
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
ClinicalTrials.gov study NCT05093335. IPD Sharing: YES. Countries: 1. Publications: 0.
CXCR4-LASP1-G9a-SNAIL Axis Drives NEPC Transdifferentiation via Induction of EMT and Downregulation of REST [331R]
GEO Series GSE296569. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Effect of the gain-of-function mutation of CXCR4 on the molecular identity of murine Skeletal Stromal/Stem Cells (SSC) and OsteoProgenitor Cells (OPC)
GEO Series GSE217422. Mus musculus. 17 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.